NIH announces new funding policy that rattles medical researchers
The National Institutes of Health has dramatically changed its grant-making terms by limiting how much it will disperse for costs such as equipment and administration.
Related Articles
The dark zone of CNS relapse in DLBCL
In this issue of Blood, Alduaij and colleagues report on central nervous system (CNS) relapse rates in a retrospective cohort of patients with high-grade B
Denial of Access to CT Screening for Nonsmokers Is Unjust
In their recent article, Silvestri et al.1 analyze results of computed tomography (CT) lung cancer screening (LCS) in Asia and argue against expansion of LCS to…
Risk factors for locoregional relapse after segmentectomy: Supplementary analysis of the JCOG0802/WJOG4607L trial
The JCOG0802/WJOG4607L trial revealed superior overall survival in segmentectomy to lobectomy for small-peripheral non-small-cell lung cancer. However, locoregional relapse (LR) is a major issue for…
Symptom monitoring with electronic patient-reported outcomes during cancer treatment: final results of the PRO-TECT cluster-randomized trial
Nature Medicine – A cluster-randomized controlled trial found that using an electronic system for symptom monitoring of patient-reported outcomes during treatment led to sustained improvements…
AACI Statement on Indirect Cost Rates | Newswise
AACI strongly opposes the decision to cut and cap reimbursement of facilities and administrative (F&A) costs—or “indirect costs”—at 15 percent for research funded by the…
Myeloma Paper of the Day, February 8th, suggested by Robert Orlowski – OncoDaily
Myeloma Paper of the Day, February 8th, suggested by Robert Orlowski / cancer, Lawrence Liu, MD Anderson Cancer Center, MGUS, Myeloma, Myeloma Paper of the
NIH reduced indirects from 60+% to 15%: 10 things you should know
Implications of Friday’s ‘enjoy your weekend’ announcement
At least 200,000 protesters rally in Munich against far-right AfD ahead of German election
More than 200,000 protesters have demonstrated in Munich against far-right extremism ahead of the German general election.
The 5th Annual OncoAlert Colloquium
The Year in Review in Oncology 2024 brought to you by some of the Worlds TOP experts!
